{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:15:05Z","timestamp":1720779305637},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1449","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:07:50Z","timestamp":1565726870000},"page":"S7-S18","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : effets secondaires n\u00e9phrologiques"],"prefix":"10.1016","volume":"98","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"N\u00e9grier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Zini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1449_bib0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1684\/bdc.2011.1449_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0015","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.2008.20.8595","article-title":"From theoretical synergy to clinical supra-additive toxicity","volume":"27","author":"Soria","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1684\/bdc.2011.1449_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0035","unstructured":"NCI. Common Toxicity Criteria, version 2.0 1999."},{"key":"10.1684\/bdc.2011.1449_bib0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","article-title":"Chemotherapy agents and hypertension: a focus on angiogenesis blockade","volume":"9","author":"Jain","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1684\/bdc.2011.1449_bib0045","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0050","first-page":"519","article-title":"Managing side effects of angiogenesis inhibitors in renal cell carcinoma","volume":"30","author":"Gr\u00fcnwald","year":"2007","journal-title":"Onkologie"},{"key":"10.1684\/bdc.2011.1449_bib0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eursup.2007.12.004","article-title":"The oncologist's view: targeted therapies in advanced renal cell carcinoma","volume":"7","author":"Bellmunt","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1684\/bdc.2011.1449_bib0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2011.1449_bib0065","unstructured":"Canadian hypertension guidelines, available at http:\/\/www.hypertension.ca."},{"key":"10.1684\/bdc.2011.1449_bib0070","first-page":"232","article-title":"Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib","volume":"105","author":"Ivanyi","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1684\/bdc.2011.1449_bib0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1179\/joc.2009.21.3.347","article-title":"Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib","volume":"21","author":"Bamias","year":"2009","journal-title":"J Chemother"},{"key":"10.1684\/bdc.2011.1449_bib0080","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.2008.21.6028","article-title":"Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?","volume":"27","author":"Bamias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1449_bib0090","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1449_bib0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1359-6349(07)70110-6","article-title":"Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management","volume":"5","author":"Negrier","year":"2007","journal-title":"Eur J Cancer Suppl"},{"key":"10.1684\/bdc.2011.1449_bib0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.12968\/bjon.2009.18.6.40767","article-title":"Managing adverse events in the use of bevacizumab and chemotherapy","volume":"18","author":"Blowers","year":"2009","journal-title":"Br J Nurs"},{"key":"10.1684\/bdc.2011.1449_bib0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"10.1684\/bdc.2011.1449_bib0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ctrv.2008.12.003","article-title":"Tolerability of first-line therapy for metastatic renal cell carcinoma","volume":"35","author":"Porta","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1684\/bdc.2011.1449_bib0115","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2011.1449_bib0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am J Med"},{"key":"10.1684\/bdc.2011.1449_bib0125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1470-2045(08)70009-3","article-title":"Quantifying hypertension in patients with cancer treated with sorafenib","volume":"9","author":"Rini","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdn729","article-title":"Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma","volume":"20","author":"Bono","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2011.1449_bib0140","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1449_bib0145","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0150","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1684\/bdc.2011.1449_bib0160","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1449_bib0165","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1684\/bdc.2011.1449_bib0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1684\/bdc.2011.1449_bib0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangi\u00e9","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0180","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","article-title":"Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis","volume":"69","author":"Hara","year":"2006","journal-title":"Kidney Int"},{"key":"10.1684\/bdc.2011.1449_bib0185","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1345\/aph.1H635","article-title":"Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma","volume":"41","author":"Barakat","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1684\/bdc.2011.1449_bib0190","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1449_bib0195","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/ndt\/gfm199","article-title":"Interstitial nephritis in a patient taking sorafenib","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1684\/bdc.2011.1449_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp603","article-title":"Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency","author":"Khan","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0205","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0210","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1684\/bdc.2011.1449_bib0215","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1449_bib0220","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-0-387-79962-9_8","article-title":"Thrombotic microangiopathy syndromes","volume":"148","author":"Zakarija","year":"2009","journal-title":"Cancer Treat Res"},{"key":"10.1684\/bdc.2011.1449_bib0225","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1684\/bdc.2011.1449_bib0230","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy: incidence, prevention and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf"},{"key":"10.1684\/bdc.2011.1449_bib0235","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.CCM.0000255916.86959.F2","article-title":"Thrombotic microangiopathy in the intensive care unit: need for strict control of blood pressure","volume":"35","author":"Vincent","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1684\/bdc.2011.1449_bib0240","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Thrombotic thrombocytopenic purpura","volume":"354","author":"George","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1449_bib0245","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00467-004-1451-y","article-title":"Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome","volume":"19","author":"Van Dyck","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1684\/bdc.2011.1449_bib0250","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1038\/sj.ki.5000375","article-title":"How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations","volume":"100","author":"Solomon","year":"2006","journal-title":"Kidney Int Suppl"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:35:20Z","timestamp":1602491720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305221"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1449","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}